TOKENPOST
1 min read
Add as a preferred source on Google

Spruce Biosciences Posts $24 Million Q3 Loss, $8.51 Per Share

Cash and cash equivalents rose to $87.7 million on Sept. 30, 2026, from $48.9 million at the end of 2025.

By John Kim
Published
An unmarked folder rests at the edge of a steel shelf / TokenPost.ai
An unmarked folder rests at the edge of a steel shelf / TokenPost.ai

Spruce Biosciences, Inc. recorded a $24.0 million net loss in the third quarter of 2026, or $8.51 per basic and diluted share.

Cash and cash equivalents totaled $87.7 million on Sept. 30, 2026, compared with $48.9 million on Dec. 31, 2025.

Spruce believes its Sept. 30 cash balance can fund planned operations and debt obligations into the second half of 2027.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…